• CSL unit Seqirus secured a UK rollout of its adjuvanted cell-based flu vaccine AUJEMFLU starting in the 2027/28 season.
• UKHSA extended its pandemic Advance Purchase Agreement with Seqirus through 2031, supporting influenza outbreak readiness tied to Liverpool manufacturing.
• Deal includes an option for the UK to buy more than 100 million doses of pandemic influenza vaccine if WHO declares a flu pandemic.
• Seqirus will keep supplying its adjuvanted egg-based flu vaccine for the 2026/27 UK season.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609211900PR_NEWS_EURO_ND__EN53102) on September 21, 2026, and is solely responsible for the information contained therein.